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Abstract
Background and Objectives: This study investigates analgesic and nociceptive effects of adding 
dexmedetomidine to bupivacaine neuraxial anesthesia through Tail-ﬂ ick (TF) and Hot-plate 
(HP) tests and the pathohistological changes on spinal nerves and nerve roots through light 
microscopy. 
Methods: Forty anesthetized, male Sprague-Dawley rats were intrathecally catheterized. Basal 
values of TF and HP tests were measured before and after catheterization. Thirty-six successfully 
catheterized rats were assigned to four groups. Group B received 10 μg bupivacaine, Group BD3 
received 10 μg bupivacaine + 3 μg dexmedetomidine, Group BD10 received 10 μg bupivacaine 
+ 10 μg dexmedetomidine and Control group received 10 μL volume of artiﬁ cial cerebrospinal 
ﬂ uid. TF and HP tests were performed between the 5th and 300th minutes of drug administration. 
Twenty-four hours after administration of drugs, rats were sacriﬁ ced and spinal cord and nerve 
roots were removed for pathological investigation. 
Results: Baseline values of the TF and HP tests were not statistically different among the groups 
(6.8 ± 0.15 s). TF and HP latencies in the Control group did not change signiﬁ cantly during the 
study. TF and HP test results showed that adding 3 and 10 μg dexmedetomidine caused a dose-
dependent increase in duration and amplitude of analgesic and nociceptive effect of bupivacaine 
(TF: 37.52 ± 1.08%, 57.86 ± 1.16% respectively, HP: 44.24 ± 1.15%, 68.43 ± 1.24% respectively).
Conclusions: There were no apparent pathohistological changes at least 24 hours after the 
intrathecal administration of a single dose of dexmedetomidine 3 μg and 10 μg. Dexmedetomidine 
added to bupivacaine for spinal block improves analgesia and prolongs block duration.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
Spinal anesthesia is the blockage of nerve transmission 
through injecting a local anesthetic agent into the cerebro-
spinal ﬂ uid 1. Its short duration of action and concerns of 
toxicity resulted in the addition of several adjunct drugs 2,3. 
Benzodiazepines 4, opioids 5, neostigmine 6, ketamine 7 and 
α2-receptor agonists 
8,9 were used to overcome these short-
ages. Many of these adjuncts have side effects like itching, 
urinary retention, respiratory depression, nystagmus, car-
diac depression, nausea and vomiting. Lacking many of the 
above-mentioned side effects and with its safer cerebral and 
respiratory proﬁ le, α2-receptor agonists prolong motor and 
sensory blockade duration, which makes them very popular 
adjuncts to neuraxial anesthesia.
In this study, we investigated how dexmedetomidine 
added to bupivacaine neuraxial anesthesia would affect 
spinal and supraspinal pain pathways through Tail-ﬂ ick (TF) 
and Hot-plate (HP) tests and its neurotoxic effect on spinal 
nerves and nerve roots through light microscopy.
Materials and Methods 
Forty male inbred Sprague Dawley rats (weight, 350-400 g; 
age, 15-16 weeks) were obtained from Pendik Faculty of 
Veterinary Science Laboratories (Istanbul, Turkey). The rats 
were housed in separate cages with unlimited water and 
food and kept in temperature controlled rooms (20-24°C, 
relative humidity 50-60%) on a 12-hour light and 12-hour dark 
cycle (dark cycle beginning at 7:00 p.m.). All tests were per-
formed in the morning. The animals were handled according 
to the “Guide for the Care and Use of Laboratory Animals” 
prepared by the Institute of Laboratory Animal Resources, 
National Research Council. The Ethical Committee of Pendik 
Faculty of Veterinary Science Laboratories, Istanbul, Turkey 
(Chairperson Dr. Muhammet AKSIN, Ph.D.) gave ethical 
approval for this study (Ethical Committee No: 13) on 19 
January 2009.
The rats were allowed to acclima ze to the laboratory 
environment for 3 days. Body weights were measured daily 
throughout the study. On the fourth day, all rats were im-
planted with an intrathecal (IT) catheter using a modiﬁ ed 
method of Yaksh 10. Anesthesia was provided with 60 mg.kg-1 in-
traperitoneal sodium pentobarbital and periodic supplements 
of 10 mg.kg-1 of pentobarbital. Response to foot stimulation 
was monitored to ensure adequacy of anesthesia. In a prone 
position, the cervical region of rats was shaved and sterilized 
with povidone-iodine. A longitudinal 2 cm incision was made 
and the neck musculature was gently retracted to expose 
the atlanto-occipital membrane. After we pierced the mem-
brane using a sterile 18-gauge disposable needle, there was 
an abundant outﬂ ow of clear cerebrospinal ﬂ uid. A stainless 
steel wire guide of a spinal needle ﬁ tting into the 32-gauge 
polyurethane (PE32) catheter was used to ease the insertion 
and prevent the catheter from bending and the traumatiza-
tion of the spinal cord. The catheter was carefully pushed 
until vertebral body T11 (7.4-7.7 cm) into the spinal space 
from the incision whilst applying slight tension to the tail in 
order to place the tip at the T11-12 vertebral level, estimated 
to be the L3-4 level of the spinal cord. After insertion, we 
aspirated and ﬂ ushed it with artiﬁ cial cerebrospinal ﬂ uid 
(ACSF) prepared using sterile water and adding commercial 
electrolyte solutions (Merck) to achieve a ﬁ nal concentra-
tion of (mEq.L-1) Na: 150, K: 3, Ca: 1.4, Mg: 0.8, P: 1 and Cl: 
155 with a pH of 7.4 11. A bacterial ﬁ lter was clamped and 
sealed on the outside end of the catheter. The incision was 
sutured and the rat returned to a separate cage for 3 days 
to recover. Rats were checked for motor or sensory deﬁ cits 
after recovery and evaluated daily by using a 4-point scale. 
Animals with any sign of neurologic deﬁ cit, infection, cath-
eter displacement or clogging were discarded. A total of 4 
animals were excluded from the study (2 because of death 
during catheterization and 2 because of infection).
Thirty-six rats were randomly assigned into four groups. 
Randomization procedure was done through computerized 
equalization of mean body weights of each group of rats. 
Drugs for IT injection were dissolved in a 10 μL volume of 
ACSF. All drugs were administered over a 1-minute time 
period. Group B received 10 μg bupivacaine, Group BD3 
received 10 μg bupivacaine + 3 μg dexmedetomidine, Group 
BD10 received 10 μg bupivacaine + 10 μg dexmedetomidine 
and Control group received 10 μL volume of ACSF on the 
fourth day after catheterization.
The TF test was structured with a heat source (100 Watt 
light bulb) focused on the dorsal surface of the tail approxi-
mately 4 cm from the tip. We measured latency in withdrawal 
from heat source. Lack of occurrence of withdrawal in 14 
seconds resulted in termination of the stimulus to avoid 
damage to the tail.
HP test was structured with a Hot Plate Analgesia Meter 
from Columbus Instruments (Columbus, OH). The surface 
of the hot plate was heated to a constant temperature of 
55oC. We measured latency to move the hind-paws or jump. 
The cutoff time was 50 seconds to avoid tissue damage. 
Baseline values of the TF and HP tests were measured on 
the ﬁ rst, fourth and seventh days. Post-injection values of 
the tests at 5th, 10th, 15th, 20th, 30th, 45th and 60th minutes 
and every 30 minutes until the 300th minute were recorded. 
Results were expressed as percentage of maximum possible 
effect (%MPE) according to the following formula: %MPE = 
(post-injection latency - pre-injection latency) x 100 / (cut-
off time - pre-injection latency). The study was performed 
double-blindly at the stages of catheterization, drug injection 
and measurements.
After the tests were completed, animals were put into 
separate cages and euthanized the next day (approximately 
24 hours after injection) with a 1 mL intra-cardiac dose of 
26% sodium thiopental and the spinal cord removed en bloc 
via a modiﬁ ed technique as described elsewhere 12. Brieﬂ y, 
after excising the surrounding skin and muscle tissue, the 
spinal column was removed and whole lumbar section was 
separated. The vertebral column was carefully cut. The dor-
sal and ventral cords were spared and cut from outside the 
vertebral foramen. During tissue removal, we veriﬁ ed the 
catheter placement. After tissue ﬁ xation in 10% neutral buff-
ered formalin (Fisher, Pittsburgh, PA) for 48 hours, sections 
were embedded in parafﬁ n, sliced in 5-10 μm thickness, and 
stained with hematoxylin-eosin, luxol fast blue, trichrome 13 
and Weil’s myeline sheath 14. Longitudinal and parallel sec-
tions were obtained at the tip of the catheter, 1 mm on either 
side of the tip, and at 2 mm intervals on either side until a 
distance of 10 mm was reached. A neuropathologist blinded 
to the injections evaluated sections. 
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Statistical Analysis
We used SPSS 17 for Windows to evaluate data. We ana-
lyzed starting weights and weight gains of rats throughout 
the study period using Student’s t-test. Distributions of TF 
and HP test results were tested using the Shapiro-Wilk test. 
Results were analyzed using variance analysis with repeated 
measures and expressed as mean ± SEM. We used Tukey’s 
procedure for post hoc comparison. We evaluated motor 
function, sensorial function and pathohistological results 
using Fisher’s exact test. Differences were considered to be 
signiﬁ cant at p < 0.05.
Results
We prepared 40 animals and analyzed the results from 36, 
as four were excluded from the study. Sta s cal analysis 
revealed a normal distribution of starting weights, no dif-
ference in trends of weight gain and rats’ food and water 
consump on throughout the study.
Evaluations using the 4-point scale showed no sign of 
neurologic deficit, infection, catheter displacement or 
clogging. Baseline values of the %MPE values in the TF and 
HP tests were not statistically different among the groups 
(using Student’s t-test) before drug administration (4 ± 1 s 
for all groups). TF and HP latencies in the Control group did 
not change signiﬁ cantly during the study. The measured pH 
values were 6.36 ± 0.05 for bupivacaine, 6.02 ± 0.04 for 
dexmedetomidine and 6.08 ± 0.04 for mixtures of dexme-
detomidine and bupivacaine.
During the TF test, 10 μg bupivacaine caused a moderate 
antinociception, which peaked at the 20th min (mean: 48.3%, 
SEM: 0.9%) and was sustained until the 240th min. Addition 
of 3 μg dexmedetomidine to 10 μg Bupivacaine caused a 
high level of antinociception, which peaked at the 30th min 
(mean: 74.4%, SEM: 1.6%) and was sustained until the 300th 
min. Addition of 10 μg dexmedetomidine to 10 μg Bupivacaine 
caused a high level of antinociception, which peaked at the 
30th min (mean: 97.9%, SEM: 1.1%) and surpassed the 300th 
min (Figure 1).
A repeated measures ANOVA test with a Greenhouse-
Geisser correction determined that mean %MPE levels 
differed statistically signiﬁ cantly between time points [F 
(8.631, 45) = 12460.737, p < 0.0005] for the TF test. Post 
hoc tests using the Tukey’s procedure revealed that 10 μg 
bupivacaine caused an increase in %MPE levels (22.07 ± 0.98% 
vs. 0.1 ± 0.1%, respectively) which was statistically signiﬁ cant 
(p < 0.001), addition of 3 μg dexmedetomidine to bupivacaine 
caused an extra increase in %MPE levels (37.52 ± 1.08%) 
which was statistically signiﬁ cant (p < 0.001), addition of 
10 μg dexmedetomidine to bupivacaine caused a further 
increase in %MPE levels (57.86 ± 1.16%) which was statisti-
cally signiﬁ cant (p < 0.001).
During HP test, 10 μg bupivacaine caused a moderate 
antinociception, which peaked at the 30th min (mean: 54%, 
SEM: 1%) and was sustained until the 300th min. Addition of 
3 μg dexmedetomidine to 10 μg Bupivacaine caused a high 
level of antinociception, which peaked at the 30th min (mean: 
76.9%, SEM: 1.7%) and was sustained until the 300th min. 
Addition of 10 μg dexmedetomidine to 10 μg Bupivacaine 
caused a high level of antinociception, which peaked at the 
15th min (mean: 98.7%, SEM: 0.5%) and surpassed the 300th 
min (Figure 2).
A repeated measures ANOVA test with a Greenhouse-
Geisser correction determined that mean %MPE levels dif-
fered statistically significantly between time points 
[F (7.655, 45) = 12612,953, p < 0.0005] for the HP test. Post 
hoc tests using the Tukey’s procedure revealed that 10 μg 
bupivacaine caused an increase in %MPE levels (28.37 ± 0.99% 
vs. 0.1 ± 0.1%, respectively) which was statistically signiﬁ cant 
(p < 0.001), addition of 3 μg dexmedetomidine to bupivacaine 
caused an extra increase in %MPE levels (44.24 ± 1.15) which 
was statistically signiﬁ cant (p < 0.001), addition of 10 μg 
Figure 1  Time course of the antinociceptive effect (%MPE) of intrathecally administered drugs measured by the TF test.
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dexmedetomidine to bupivacaine caused a further increase 
in %MPE levels (68.43 ± 1.24%) which was statistically sig-
niﬁ cant (p < 0.001).
At the 24th hour after injections, cellular structure was 
preserved on all slides. No pathologic change was noted in 
grey and white matter, dural, pial and arachnoid membranes. 
Spinal nerve roots and ganglion cells retained their morphol-
ogy. There was no apparent neurotoxicity at least 24 hours 
after the administration of single dose of dexmedetomidine 
3 μg and 10 μg (p > 0.05).
Discussion 
This study showed that addition of dexmedetomidine to 
bupivacaine spinal block enhances the amplitude and dura-
tion of nociception to a thermal stimulus. Dexmedetomidine 
acts on several places to show its antinociceptive action. It 
binds to presynaptic C-ﬁ bers transmitting noxious stimuli 
from peripheral receptors to spinal cord. It also binds to 
α2A- and α2C-adrenoceptors of postsynaptic neurons present 
in superﬁ cial layers of the spinal dorsal horn 15. Its antino-
ciceptive effects result both from inhibition of presynaptic 
C-ﬁ bers and hyperpolarization of postsynaptic dorsal horn 
neurons 16. Ishii and colleagues reported that dexmedeto-
midine induced activation of K+-channels through α2A- and 
α2C-adrenoceptors results in hyperpolarization of substantia 
gelatinosa neurons 15. Similarly, Brummett and colleagues 
reported that dexmedetomidine’s antinociceptive action 
depends on inhibiting the build up of excitation via hyper-
polarization-activated cation current (Ih) and is reversed by 
Ih agonist forskolin 
17.
Among spinal catheterization methods, sacral approach 
is mainly suited for epidural drug administration and lumbar 
approach carries the risks of bone damage and inﬂ ammation 
due to ﬁ xatives. Therefore the atlanto-occipital approach has 
been preferred as it was well described by Yaksh et al. 10. PE32 
catheters were used to minimize damage to spinal cord and 
nerve roots 2. We chose the spinal route for drug delivery to 
eliminate the concerns about insufﬁ cient diffusion of drugs 
through dural membrane and also to observe the effect of 
drugs, pH and catheters on spinal cord.  Several studies 
veriﬁ ed accurate placement of perineural catheter using 
lidocaine or any local anesthetic to produce a motor block. 
In our study, no drug other than the study ones were injected 
through the catheters to minimize effects, therefore catheter 
placement was veriﬁ ed by postmortem examination.
Our study showed that dexmedetomidine dose depend-
ently prolonged the duration and augmented the analgesic 
quality of the spinal block. Our results concord with Calasans 
and colleagues’ study reporting that levobupivacaine-induced 
spinal block was prolonged by intrathecal dexmedetomi-
dine in doses up to 0.4 μg and intraperitoneal doses up to 
40 μg.kg-1, which was reversed by an α-adrenergic antago-
nist, yohimbin 18. These results suggest that dexmedetomi-
dine exerts its effects through α2-adrenoceptor agonism. 
Brummett and colleagues’ study investigating addition of 
dexmedetomidine to ropivacaine induced peripheral nerve 
block 19. They administered dexmedetomidine in doses up to 
20 μg.kg-1, and the pH value of mixture of ropivacaine and 
dexmedetomidine was reported to be 5.69 ± 0.05, which is 
far more acidic than the pH values of drug mixtures meas-
ured in our study. This and the fact that a pathohistological 
examination of nerve tissues were done after 24h of drug 
administration may explain why our study did not show signs 
of inﬂ ammation or nerve damage.
The TF response is organized at the spinal level, the HP 
response is mediated by both spinal and supraspinal levels 20. 
The increase in withdrawal latency times in our study was 
similar in both TF and HP test results. This may suggest that 
intrathecally administered dexmedetomidine did not reach 
the supraspinal centers or that its effects on supraspinal 
centers were less prominent than on dorsal horn neurons.
In two different studies investigating dexmedetomidine’s 
effects on nerve blocks, onset time of nerve blocks are re-
ported to be shortened by Gupta and colleagues investigating 
spinal block in lower abdominal surgery and Esmaoglu and 
Figure 2  Time course of the antinociceptive effect (%MPE) of intrathecally administered drugs measured by the HP test.
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colleagues investigating axillary nerve blocks 16,21. In our 
study, the ﬁ rst measurements in both tests were done at the 
ﬁ fth minute, which prevented the study to show a possible 
difference between the start times of the anti-nociceptive 
effect. Since the anesthesia start time is of critical impor-
tance in regional anesthesia, frequent measurements starting 
earlier are needed to clarify any possible difference.
Conclusion
Dexmedetomidine added to bupivacaine for spinal block 
improves analgesia and prolongs block duration.
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